Cancer Research and Treatment

Lung Cancer in Korea: Hoon Kyo Kim; Cancer Res Treat. 2002;34(1):1-2. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.1

Abstract PDF

No abstract available.

Citations

Citations to this article as recorded by

Microtubule‐damaging agents enhance RASSF1A‐induced cell death in lung cancer cell lines
Young Mi Whang, Kyong Hwa Park, Hae‐Yun Jung, Uk Hyun Jo, Yeul Hong Kim
Cancer.2009; 115(6): 1253. CrossRef
The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population
Uk Hyun Jo, Sle Gi Lo Han, Jae Hong Seo, Kyong Hwa Park, Jae Won Lee, Hyo Jung Lee, Jeong Seon Ryu, Yeul Hong Kim
BMC Cancer.2008;[Epub] CrossRef
Combination of PTEN and γ-Ionizing Radiation Enhances Cell Death and G2/M Arrest Through Regulation of AKT Activity and p21 Induction in Non–Small-Cell Lung Cancer Cells
Jong Kuk Park, Hae-Yun Jung, Seon Ho Park, Seung Yi Kang, Mi-Rang Yi, Hong Duck Um, Sung Hee Hong
International Journal of Radiation Oncology*Biology*Physics.2008; 70(5): 1552. CrossRef
Putative association of the single nucleotide polymorphisms in RASSF1A promoter with Korean lung cancer
Jae Sook Sung, Sle Gi Lo Han, Young Mi Whang, Eun Soon Shin, Jae Won Lee, Hyo Jung Lee, Jeong-Seon Ryu, In Keun Choi, Kyong Hwa Park, Jun Suk Kim, Sang Won Shin, Elizabeth K. Chu, Yeul Hong Kim
Lung Cancer.2008; 61(3): 301. CrossRef
AKAP12α is AssoCiated with Promoter Methylation in Lung Cancer
Ukhyun Jo, Young Mi Whang, Han Kyeom Kim, Yeul Hong Kim
Cancer Research and Treatment.2006; 38(3): 144. CrossRef

4,256 View
25 Download
5 Crossref

Epidemiology of Lung Cancer in Korea: Choon Taek Lee; Cancer Res Treat. 2002;34(1):3-5. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.3

Abstract PDF

No abstract available.

Citations

Citations to this article as recorded by

Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma
Jeong-Sun Seo, Ji Won Lee, Ahreum Kim, Jong-Yeon Shin, Yoo Jin Jung, Sae Bom Lee, Yoon Ho Kim, Samina Park, Hyun Joo Lee, In-Kyu Park, Chang-Hyun Kang, Ji-Young Yun, Jihye Kim, Young Tae Kim
Cancer Immunology Research.2018; 6(7): 848. CrossRef
Comorbidities of rheumatoid arthritis: Results from the Korean National Health and Nutrition Examination Survey
Hyemin Jeong, Sun Young Baek, Seon Woo Kim, Yeong Hee Eun, In Young Kim, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh, Hoon-Suk Cha, Shian-Ying Sung
PLOS ONE.2017; 12(4): e0176260. CrossRef
Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer
Jing Deng, Wei Jia Fang, Xiao Chen Zhang, Dong Ping Wu, Hong Ming Fang, Jing Chen, Jiong Qian, Hai Bo Mou, Bin Bin Chu, Nong Xu, Li Song Teng
Medical Oncology.2012; 29(2): 595. CrossRef
Comparison of ThinPrep Cytology and Conventional Cytology in Bronchial Washing for Lung Cancer
Jungsuk An, Hyun Yee Cho, Dong Hae Chung, Seung Yeon Ha
Journal of Lung Cancer.2012; 11(2): 84. CrossRef
Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy
Hua-qi Zhang, Jin-ming Yu, Xue Meng, Jin-bo Yue, Rui Feng, Li Ma
European Journal of Radiology.2011; 77(1): 92. CrossRef
Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentations in Non-Small Cell Lung Cancer
Im Il Na, Jong Heon Park, Du Hwan Choe, Jin Kyung Lee, Jae Soo Koh
ISRN Oncology.2011; 2011: 1. CrossRef
Oncological Safety and Quality of Life Associated with Mastectomy and Immediate Breast Reconstruction with a Latissimus Dorsi Myocutaneous Flap
Sun Young Min, Hyun Yul Kim, So-Youn Jung, Youngmee Kwon, Kyung Hwan Shin, Seeyoun Lee, Seok Won Kim, Han-Sung Kang, Young Ho Yun, Eun Sook Lee
The Breast Journal.2010; : no. CrossRef
18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis
Im Il Na, Byung Hyun Byun, Kyeong Min Kim, Gi Jeong Cheon, Du Hwan Choe, Jae Soo Koh, Duck Yong Lee, Baek-Yeol Ryoo, HeeJong Baek, Sang Moo Lim, Sung Hyun Yang, Cheol Hyeon Kim, Jae Cheol Lee
Lung Cancer.2010; 67(1): 76. CrossRef
Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer
Im Il Na, Du Hwan Choe, Cheol Hyeon Kim, Jae Soo Koh, Baek-Yeol Ryoo, Jae Cheol Lee, Sung Hyun Yang
Lung Cancer.2010; 68(2): 295. CrossRef
Clinical significance of 18F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: A retrospective study
Im Il Na, Gi Jeong Cheon, Du Hwan Choe, Byung Hyun Byun, Hye Jin Kang, Jae Soo Koh, Jong Ho Park, HeeJong Baek, Baek-Yeol Ryoo, Jae Cheol Lee, Sung Hyun Yang
Lung Cancer.2008; 60(1): 69. CrossRef
A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer
Im Il Na, Tae Hyun Lee, Du Hwan Choe, Gi Jeong Cheon, Cheol Hyeon Kim, Jae Soo Koh, HeeJong Baek, Baek-Yeol Ryoo, Sung Hyun Yang, Jae Cheol Lee
European Journal of Cancer.2008; 44(16): 2411. CrossRef
18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non–Small Cell Lung Cancer
Im Il Na, Byung Hyun Byun, Hye Jin Kang, Gi Jeong Cheon, Jae Soo Koh, Cheol Hyeon Kim, Du Hwan Choe, Baek-Yeol Ryoo, Jae Cheol Lee, Sang Moo Lim, Sung Hyun Yang
Clinical Cancer Research.2008; 14(7): 2036. CrossRef
A Comparison of Conventional Cytology and ThinPrep Cytology of Bronchial Washing Fluid in the Diagnosis of Lung Cancer
Sang-Hoon Kim, Eun Kyung Kim, Kyeh-Dong Shi, Jung-Hyun Kim, Jeong-Hwan Yoo, Kyung Soo Kim, Joo-Young Kim, Gwang-Il Kim, Hee-Jung An, Ji-Hyun Lee
Tuberculosis and Respiratory Diseases.2007; 62(6): 523. CrossRef
A Phase II Study of Single-Agent Gemcitabine as a Second-Line Treatment in Advanced Non-Small Cell Lung Cancer
Keun-Hyok Cho, Young-Bong Song, Ik-Sung Choi, Eun-Hee Cho, Jae-Won Choi, Young Mi Ahn, Yong Ho Roh, Seung-Hyun Nam, Bong-Seog Kim
Japanese Journal of Clinical Oncology.2006; 36(1): 50. CrossRef
Lung Cancer : Overview
Jin Soo Lee
Journal of the Korean Medical Association.2003; 46(1): 7. CrossRef

3,970 View
23 Download
15 Crossref

Genetic Susceptibility to Lung Cancer in Koreans: Jae Yong Park; Cancer Res Treat. 2002;34(1):8-12. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.8

Abstract PDF

No abstract available.

Citations

Citations to this article as recorded by

Tobacco, Genetic Susceptibility and Lung cancer
Ravindran Ankathil
Tobacco Use Insights.2010;[Epub] CrossRef

3,955 View
20 Download
1 Crossref

Lung Cancer Screening with Low-Dose Spiral CT: Myeong Im Ahn; Cancer Res Treat. 2002;34(1):13-16. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.13

Abstract PDF: No abstract available.

3,323 View
20 Download

Loss of CD10/NEP Expression in the Pulmonary Carcinogenesis: Nahye Myoug; Cancer Res Treat. 2002;34(1):17-22. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.17

Abstract PDF: PURPOSE
S: The cell surface metalloproteinase CD10/ neutral endopeptidase 24.11 (NEP) hydrolyzes a variety of peptide substrates and reduces cellular responses to specific peptide hormones. CD10/NEP has been recognized as modulating peptide-mediated proliferation of lung carcinomas and the normal airway epithelium. The purposes of this study are to evaluate the expression of CD10/NEP in human lung cancers, including non- small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), and to correlate its expression with several clinicopathologic parameters, including proliferative activity.
MATERIALS AND METHODS
CD10/NEP expression and proliferative activity were evaluated by immunohisto chemistry in 55 formalin-fixed and paraffin-embedded NSCLC and SCLC specimens, using anti-Human CD10/ NEP and Ki-67 primary antibodies. The correlations between CD10/NEP expression and either Ki-67 proliferative activity or several clinicopathologic parameters were analyzed by chi-square test or Fisher's exact test.
RESULTS
Most NSCLC (76%) and SCLC (80%) cases showed loss of CD10/NEP expression in the tumor cells, whereas the bronchial and alveolar epithelia and stromal fibroblasts in the adjacent healthy lung revealed strong expression of CD10/NEP. Its expression was not correlated with proliferative activity or any of the clinicopathologic parameters except for age. Only in terms of topographical expression was CD10/NEP expression found to be inversely correlated with Ki-67 proliferative activity.
CONCLUSION
These results suggest that loss of CD10/ NEP expression may be important in the pulmonary carcinogenesis of both NSCLCs and SCLCs, which is topographically related to NSCLC proliferative activity, especially in the squamous cell type.

3,273 View
18 Download

A Phase II Study with Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer: Jae Wan Park, Hwan Yang Park, Yong Bae Park, Jung Won Kang, Sung Hung Kim, Gwi Lae Lee, Bong Seog Kim, Yong Ho Roh; Cancer Res Treat. 2002;34(1):23-27. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.23

Abstract PDF

PURPOSE
To evaluate the efficacy and safety of gemcitabine and carboplatin (GC) in the treatment of advanced non-small-cell lung cancer (NSCLC).
MATERIALS AND METHODS
Between November 1999 and April 2001, 34 patients were enrolled in this study. The median age was 66 (range: 52-74) years old and all were male. Sixteen patients demonstrated stage IIIB, 15 stage IV, and 3 recurrence of disease after surgery. Twenty-two patients showed a ECOG performance status of 0 or 1 and 12 had 2. Twenty patients presented with squamous cell carcinoma, 11 adenocarcinoma and 3 unclassified NSCLC. The treatment regimen consisted of intravenous carboplatin AUC of 6 on day 1 and gemcitabine 1,250 mg/m2 on day 1 and 8. The treatment was repeated every 28 days. Toxicities were evaluated according to WHO toxicity criteria.
RESULTS
All thirty-four patients were evaluable. Partia responses were observed in 15 patients. The overall response rate was 44% (95% confidence interval: 27-61%) and the median response duration was 26 (range 8-60 ) weeks. The median survival of all patients was 50 (range 8-70 ) weeks. During a total of 144 cycles, granulocytopenia greater than WHO grade 2 occurred in 2%, thrombocytopenia in 2%, and anemia in 3%, respectively. Non- hematologic toxicities were minor and easily controlled.
CONCLUSION
A combination chemotherapy of intravenous gemcitabine and carboplatin has a relatively high activity with acceptable toxicities in patients with advanced NSCLC.

Citations

Citations to this article as recorded by

A Phase II Study of Single-Agent Gemcitabine as a Second-Line Treatment in Advanced Non-Small Cell Lung Cancer
Keun-Hyok Cho, Young-Bong Song, Ik-Sung Choi, Eun-Hee Cho, Jae-Won Choi, Young Mi Ahn, Yong Ho Roh, Seung-Hyun Nam, Bong-Seog Kim
Japanese Journal of Clinical Oncology.2006; 36(1): 50. CrossRef
A 21-day Schedule of Gemcitabine and Cisplatin Administration in the Treatment of Advanced Non-Small Cell Lung Carcinoma: a Phase II Study
Jong-Sung Park, Chang-Min Lee, Shin-Ae Lee, Chang-kil Jung, Sung-Hyun Kim, Hyuk-Chan Kwon, Jae-Seok Kim, Hyo-Jin Kim
Cancer Research and Treatment.2004; 36(1): 62. CrossRef

4,383 View
18 Download
2 Crossref

Efficacy of Combination Chemotherapy with Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer: Eun Jung Rhee, Hyun Sik Jeong, Seung Sei Lee; Cancer Res Treat. 2002;34(1):28-33. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.28

Abstract PDF

PURPOSE
To evaluate the efficacy and toxicity of the combination therapy of paclitaxel and cisplatin in advanced, non-small cell, lung cancer patients MATERIALS AND METHODS: Between December 1997 and September 2001, 37 patients with advanced, non-small cell, lung cancer were enrolled in this study. Patients were treated with paclitaxel (135 mg/m2, 24 hr infusion) and cisplatin (75 mg/m2). The treatments were repeated every 4 weeks.
RESULTS
Among the 37 patients enrolled, 21 were treated with paclitaxel and cisplatin as a first-line and 16 patients as a second-line. The median age of the patients was 59. In the first-line group, 10 had stage IIIB and 11 had stage IV, non small cell lung cancer. Of 21 patients in first-line treatment group that could be evaluated, objective responses were observed in 6 patients (response rate: 28.6%, CR: 4.8%, PR: 23.8%). The mediansurvival duration for patients was 48 weeks. With the second-line group, 3 patients showed a partial response (response rate: 18.7%) to treatment, with median survival duration of 44 weeks. Grade 3-4 leukopenia was observed in 27.1% of the first-line, and 23.6% in second- line, treatment groups.
CONCLUSION
Combination chemotherapy, with paclitaxel and cisplatin, in non-small cell lung cancer has acceptable toxicities in both first and second-line treatment groups. In terms of efficacy, no superior response was shown for either group. More randomized studies, with a larger group of patients, are required to prove the true efficacy.

Citations

Citations to this article as recorded by

Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments
Xiaomeng Wan, James J. Beaudoin, Natasha Vinod, Yuanzeng Min, Naoki Makita, Herdis Bludau, Rainer Jordan, Andrew Wang, Marina Sokolsky, Alexander V. Kabanov
Biomaterials.2019; 192: 1. CrossRef
Proximal Gastrectomy Reconstructed by Jejunal Pouch Interposition for Upper Third Gastric Cancer: Prospective Randomized Study
Chang Hak Yoo, Byung Ho Sohn, Won Kon Han, Won Kil Pae
World Journal of Surgery.2005; 29(12): 1592. CrossRef
Long-term Results of Proximal and Total Gastrectomy for Adenocarcinoma of the Upper Third of the Stomach
Chang Hak Yoo, Byung Ho Sohn, Won Kon Han, Won Kil Pae
Cancer Research and Treatment.2004; 36(1): 50. CrossRef

4,258 View
44 Download
3 Crossref

Clinical Significance of p53, P-glycoprotein, and Glutathione S transferase-pi in Advanced Non-Small Cell Lung Cancer: Young Don Joo, Chang Hak Sohn; Cancer Res Treat. 2002;34(1):34-40. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.34

Abstract PDF: PURPOSE
A retrospective study was performed o define the clninical significance of p53, P-glycoprotein (Pgp), and Glutathione S transferase-pi (GST-pi) immunohistochemical (IHC) expression in advanced non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS
We reviewed fifty seven patients with advanced NSCLC who had undergone surgical resection or bronchoscopic biopsy between March 1997 and March 1999. IHC staining for p53, GST-pi, and Pgp was performed using formalin-fixed, paraffin-embedded specimens of the fifty seven patients.
RESULTS
The IHC expression rate was 63% for p53, 28% for Pgp, and 53% for GST-pi, respectively. The median survival of the fifty seven patients was 45 weeks and the response rate was 38.6% (partial response, 22/57). The chemotherapy response and median survival of the p53 negative group (57% and 61 weeks) were better than those demonstrated by the p53 positive group (28% and 21 weeks) (p<0.05). Additionally, the GST-pi negative group showed a greater improvement of survival and response rate than the positive group (p<0.05). Pgp expression status appeared to have no significant differential effect on chemotherapy response and survival.
CONCLUSION
These results suggest that immunohisto chemical staining of p53 and GST-pi may be useful in predicting the response to chemotherapy as well as survival in advanced NSCLC. However, this study is limited by its retrospective nature and the small numbers of tumors studied from a heterogenous group of patients.

3,886 View
24 Download

Correlation of Mast Cell Densities, Angiogenesis and Vascular Endothelial Growth Factor in Proper Muscle Gastric Carcinomas: Eun Sook Nam, Duck Hwan Kim, Gi Taek Jang, Hae Rim Park, Jeong Rye Kim, Hyung Sik Shin; Cancer Res Treat. 2002;34(1):41-45. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.41

Abstract PDF

PURPOSE
There are increasing evidences that angiogenesis enhances tumor growth and biological aggressiveness in gastric carcinoma. Mast cells have been implicated in the angiogenic process, by secreting angiogenic factors including vascular endothelial growth factor (VEGF), or enzymes that degrade extracellular matrices. However, the exact nature of mast cells in relation to cancer is contradictory so we conducted retrospective studies, to find the significance of mast cell densities, and microvessel counts in each clinicopathologic factors, including VEGF expression, in proper muscle (PM) gastric carcinoma.
MATERIALS AND METHODS
52 specimens, obtained from patients with PM gastric carcinoma, were studied using the immunohistochemical methods, monoclonal antibodies for mast cell tryptase, factor VIII-related antigen and VEGF.
RESULTS
Mast cell densities were significantly increased in diffuse histologic type (p=0.042), infiltrating margins (p<0.0001) and VEGF positive (p=0.010) tumors.Microvessel counts were significantly higher in patients over 55 years old (p=0.024), with tumor sizes larger than >3 cm (p=0.015), diffuse histologic type (p=0.038) and lymph node metastasis (p=0.001). Similarly there were significantly increased densities in VEGF positive tumors (p<0.0001). Pearson's correlation analysis revealed a significant relationship between mast cell densities and microvessel counts (r=0.614, p<0.01), indicating a high vascular grade with increased number of mast cells.
CONCLUSION
We demonstrated a close relationship between mast cell densities, microvessel counts and VEGF expression. These results suggest that mast cells and VEGF are important regulators of tumor angiogenesis and cooperatively induce the formation of vascular stroma in PM gastric carcinomas.

Citations

Citations to this article as recorded by

Mast Cells Density Positive to Tryptase Correlate with Microvascular Density in both Primary Gastric Cancer Tissue and Loco-Regional Lymph Node Metastases from Patients That Have Undergone Radical Surgery
Michele Ammendola, Rosario Sacco, Valeria Zuccalà, Maria Luposella, Rosa Patruno, Pietro Gadaleta, Nicola Zizzo, Cosmo Gadaleta, Giovambattista De Sarro, Giuseppe Sammarco, Mihai Oltean, Girolamo Ranieri
International Journal of Molecular Sciences.2016; 17(11): 1905. CrossRef

4,066 View
23 Download
1 Crossref

Telomerase Activity and Expression of hTR and TERT in Human Soft Tissue Sarcomas: Jinyoung Yoo, Seok Jin Kang, Byung Kee Kim; Cancer Res Treat. 2002;34(1):46-51. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.46

Abstract PDF

PURPOSE
Sarcomas have rarely been analyzed for telomerase, which is an RNA-dependent DNA polymerase to maintain telomeres and prevent telomere shortening. This study was undertaken to determine telomerase activity and the expression of the telomerase subunits human telomerase RNA (hTR) and telomerase reverse transcriptase (TERT) in soft tissue sarcomas.
MATERIALS AND METHODS
Twenty three sarcomas were analyzed for the telomerase activity by a radioactive PCR-based TRAP assay. All of the samples were further investigated for the expression of hTR by in situ hybridization and for TERT and p53 by immunohistochemistry.
RESULTS
Telomerase activity was detected in four (17%) samples. Expression of hTR was demonstrated in 11 (48%) cases, whereas TERT was expressed in 20 (87%).Of the four telomerase-positive tumors, three were positive for both hTR and TERT, and one was positive only for TERT. p53 overexpression was observed in nine (39%) tumors. The frequency of p53 expression increased as the tumor grade advanced (p= .064).
CONCLUSION
These data indicate that the reactivation of telomerase is an uncommon event in human soft tissue sarcomas. The high frequency of the expression of hTR and TERT in these tumors suggests that telomerase activity may be regulated at the transcriptional level and an additional event leading to telomerase activation exist.

Citations

Citations to this article as recorded by

Concomitant underexpression of TGFBR2 and overexpression of hTERT are associated with poor prognosis in cervical cancer
Hui Yang, Hongyan Zhang, Yahua Zhong, Qiaoli Wang, Lei Yang, Hong Kang, Xiaojia Gao, Haijun Yu, Conghua Xie, Fuxiang Zhou, Yunfeng Zhou
Scientific Reports.2017;[Epub] CrossRef

4,319 View
28 Download
1 Crossref

Expression of Cell Surface Receptors on Human Glioblastoma Xenograft Model in NOD/SCID Mouse: Kyung Seung Oh, Ki Uk Kim, Na Hee Park, Su Yeong Seo, Sun Seob Choi, Gi Yeong Huh; Cancer Res Treat. 2002;34(1):52-57. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.52

Abstract PDF: PURPOSE
To obtain basic data for development of a glioblastoma-specific immunotoxin, the expression of variable cell surface receptors on a human glioblastoma xenograft model was evaluated, using NOD/SCID mice.
MATERIALS AND METHODS
We developed a xenograft model in NOD/SCID mice implanted with a human glioblastoma cell line (U-87MG). Immunohistochemical studies were performed on implanted tumor nodules (n=8) using antibodies against CD71, EGFR, IGF-IRalpha, CXCR4 and IL-4Ralpha.
RESULTS
Expression of IL-4Ralpha, in implanted tumornodules, was the highest of the cell surface receptors evaluated in this study. However, the endothelial cells in, and around, the tumor nodules also revealed immunopositivity against IL-4Ralpha. The immunoreactivity of IL-4Ralpha, and other surface receptors such as CD71, IGF-IRalpha and EGFR, was prominent in tumor nodules associated with tumor necrosis.
CONCLUSION
IL-4Ralpha would be a possible target for the development of glioblastoma-specific immunotoxin, although there are limitations due to its endothelial expression.

4,258 View
28 Download

Conjunctival Lymphoma: Retrospective Analysis of the Treatment Result and Complications with Radiation Therapy: Kyoung Ju Kim, Seung Do Ahn, Eun Kyung Choi, Hyesook Chang, Jong Hoon Kim; Cancer Res Treat. 2002;34(1):58-61. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.58

Abstract PDF: PURPOSE
In order to evaluate the response to radiation therapy and to analyze the patterns of failure, survival and complications, we performed a retrospective analysis of patients with conjunctival lymphoma.
MATERIALS AND METHODS
From November 1991 to March 1999, 11 patients were diagnosed as conjunctival lymphoma at Asan Medical Center. Five patients had bilateral involvements, and a total of 16 eyes received radiation therapy. Using 6 to 9 MeV electrons or 4 MV photon beams, all patients were treated with a single anterior field to total doses ranging from 30 Gy to 45 Gy delivered in 10 to 25 fractions. The median follow up period was 57 Months.
RESULTS
All patients achieved a complete response with radiation therapy. Two of 16 eyes that were treated (12.5%) developed local recurrence after radiation therapy, however they were salvaged with 30 Gy of reirradiation. The five-year local control was 88.9%. One out of 11 patients (9.9%) developed lung metastasis and received chest irradiation. At the last follow up, one had died of pneumonia and 10 patients were alive without disease evidence. The five-year overall survival rate was 77.8% and 5-year disease free survival was 77.8%. Cataract and dry eye occurred in one patient (9.9%) respectively.
CONCLUSION
Radiation therapy is a very effective and safe treatment modality for conjunctival lymphoma. The local control rate of radiotherapy was excellent and complications were acceptable. Radiation therapy is also an effective treatment modality for recurrent conjunctival lymphoma. It generally requires more than three months to achieve complete response following radiation therapy, thus we recommend evaluating the response to radiation therapy at three months after completion of treatment.

4,313 View
25 Download

Sclerotheraphy with OK-432 for the Treatment of Lymphangiomas: Young Gwon Wang, Hyung Il Seo, Hae Young Kim; Cancer Res Treat. 2002;34(1):62-66. Published online February 28, 2002; DOI: https://doi.org/10.4143/crt.2002.34.1.62

Abstract PDF

PURPOSE
To evaluate the efficacy of sclerotherapy with OK-432 for lymphangiomas.
MATERIALS AND METHODS
Retrospective review of twelve patients with lymphangiomas who were treated with OK-432 from 1996 to 2000.
RESULTS
Twelve patients were treated by sclerotherapy with OK-432. Ten patients were received sclerotherapy with OK-432 as primary therapy, and two were treated as secondary therapy after failure of surgery. Six cases were cystic hygroma (macrocystic); all of them, complete shrinkage was obtained. The other six cases were cavernous lymphangioma (microcystic): two of them, therapy were successful, but four were failed to achieve satisfactory shrinkage. So, they underwent surgical excision after failure of sclerotherapy. The results were excellent in cystic hygroma (success rate; 100%), however moderately poor results were obtained in cavernous lymphangioma (success rate 33.3%).
CONCLUSION
Intralesional injection of OK-432 is effective therapy for cystic hygroma as a primary therapy.

Citations

Citations to this article as recorded by

Sclerotherapy in the Management of Oral Mucocele
Trupti Vijay Gaikwad, Anuj Paul Maini, Arunima Sarma, Sukanya Das, Sayali Lokhande, Shristi Rakesh Prasad
Journal of the International Clinical Dental Research Organization.2022; 14(2): 96. CrossRef

3,812 View
29 Download
1 Crossref

Previous issues